| Active substance | Fenfluramine hydrochloride |
| Holder | UCB PHARMA NV |
| Status | Running |
| Indication | treatment of patients with CDKL5 deficiency disorder who completed study ZX008-2103 (EP0216; EudraCT number 2021-003222-76) |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 18/03/2025 |